Combination of MK3475 and Metronomic Cyclophosphamide in Patients With Advanced Sarcomas : Multicentre Phase II Trial
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 163
Summary
- Conditions
- Sarcoma
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: Non-RandomizedIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
This is a phase 2 trial with 7 strata : Leiomyosarcoma (strata 1) : 33 patients Undifferentiated sarcoma (strata 2): 33 patients Sarcomas others (strata 3) : 33 patients Osteosarcoma (strata 4) : 33 patients GIST (strata 5): 31 patients Advanced soft-tissue sarcoma with immune signature (strata 6): ...
This is a phase 2 trial with 7 strata : Leiomyosarcoma (strata 1) : 33 patients Undifferentiated sarcoma (strata 2): 33 patients Sarcomas others (strata 3) : 33 patients Osteosarcoma (strata 4) : 33 patients GIST (strata 5): 31 patients Advanced soft-tissue sarcoma with immune signature (strata 6): 32 patients Metastatic soft-tissue sarcoma (strata 7): 32 patients
Tracking Information
- NCT #
- NCT02406781
- Collaborators
- Merck Sharp & Dohme Corp.
- Ministry of Health, France
- Immune Design
- Investigators
- Study Chair: Antoine ITALIANO, MD, PhD Institut Bergonié
Get Well Soon